NewTimeSpace News: SG Group Holdings announced via an announcement dated June 24 that the Company has appointed Sky Pillar Capital Limited as its independent financial adviser to advise the independent board committee and independent shareholders in connection with the offer matters.
NewTimeSpace News: Shanxi Installation announced on June 24 that the second tranche of its 2026 publicly offered corporate bonds targeted at professional investors has been fully issued, with an actual issuance size of RMB 350 million and a coupon rate of 2.37%.
NewTimeSpace News: CIG SHANGHAI CO., LTD. announced on June 24 that the cumulative deviation in closing price increase of its A-shares has reached 20% across three consecutive trading days from June 22 to June 24, triggering abnormal price fluctuation. After verification, Cambridge Industries Group confirmed there are no material matters that ought to be disclosed but have not yet been announced.
NewTimeSpace News: UNI-BIO SCIENCE GROUP LIMITED announced on June 24 that the company has granted an aggregate of 300 million share options to four eligible participants at an exercise price of HK$0.09 per share.
NewTimeSpace News: Dobot Technology announced via an announcement dated June 24 that the company has authorised its trustee to purchase H-shares from the secondary market at an aggregate total consideration not exceeding HK$200 million pursuant to its H-share incentive scheme, to satisfy future award grants under the scheme.
NewTimeSpace News: Seyond Holdings Ltd. announced on June 25 that shareholders Honour Key Limited and Glory Summer Worldwide Limited have voluntarily entered into a lock-up commitment. Between June 25, 2026 and December 9, 2026, they will not dispose of their combined holding of approximately 148 million shares via secondary market bidding transactions at a price below HK$10 per share.
NewTimeSpace News: Antengene disclosed in an announcement on June 25 that its board of directors resolved to repurchase shares worth a maximum of HK$50 million on the open market funded by internal resources, in accordance with the share repurchase general mandate approved at the annual general meeting.
BIOSYSEN (01355.HK) plans to conduct a rights issue on the basis of \"2 for 1\", with estimated net proceeds of HKD 39 million.
Sirnaomics (2257.HK) announced that its executive director and chairman Dr. Patrick Lu purchased an aggregate of 20,300 ordinary shares on the open market on June 24, 2026, at an average price of approximately HK$5.00 per share using personal funds, bringing his total interest to 17,685,996 shares, representing 16.12% of total issued share capital. Dr. Lu expressed full confidence in the Group's development prospects and potential growth, and does not rule out further increasing his shareholding at an appropriate time subject to applicable laws and regulations.
Hanx Biopharmaceuticals (3378.HK) announced that all controlling shareholders have voluntarily extended their lock-up period by 12 months to December 22, 2027, undertaking not to reduce holdings in any manner; certain pre-IPO shareholders extended by 6 months to June 22, 2027, and certain cornerstone investors extended by 7 months to January 22, 2027. Cai Zhang Biotech and two other controlling shareholders collectively hold approximately 76.14 million shares, while seven pre-IPO investors including Beijing Longpan collectively hold approximately 25.05 million shares. The Company believes the extensions demonstrate shareholders' confidence in future prospects, core technology, and long-term value, with potential for further extensions based on business development.
OCT Asia (03366.HK) announced that Hefei OCT Industrial entered into the Hefei land resumption agreement with Hefei Municipal Land Reserve Center on June 17, 2026, with total compensation of RMB1.725 billion; the first installment of RMB1.33 billion was received on June 24, 2026, while the remaining RMB395 million is expected to be paid within two years after land listing and completion of delivery procedures; as of the announcement date, the Chaohu agreement has not yet been signed, and the proposed disposals may not proceed.
Mabpharm (2181.HK) announced that its pipeline product CMAB807X Leishu® (denosumab injection) has received NMPA approval for its NDA, with indications covering the treatment of solid tumor bone metastasis or multiple myeloma patients to delay or reduce skeletal-related event risks, and giant cell tumor of bone that is unresectable or where surgery would cause severe morbidity, including adults and skeletally mature adolescents.
China Art Financial (1572.HK) announced that its subsidiary Jingdong Holdings (Shenzhen) signed a cooperation agreement with Shenzhen Cultural Property Exchange on June 17, 2026, to provide agency trading, consulting and other services within Shenzhen CEx's cultural big data application trading and operation service center; Shenzhen CEx is a national-level key cultural element trading market controlled by Shenzhen Media Group and authorized by the Ministry of Finance as a designated trading platform for central cultural enterprises' state-owned property rights, and the Group expects the cooperation to generate new recurring revenue streams as it strategically enters the cultural big data sector.
By the close of trading on Jun 24, 2026, YSB(09885.HK) saw a gain of 16.52% in its share price, closing at HKD 3.88. and touched an intraday low of HKD 3.18.
By the close of trading on Jun 24, 2026, MICOT PHARMA-B(02335.HK) saw a gain of 102.75% in its share price, closing at HKD 36.9. During the session, it reached an intraday high of HKD 37.1 and touched an intraday low of HKD 32.2.
TENCENT(00700.HK) will spend HKD 500.73 million to repurchase 1.18 million shares on Jun 24, 2026 .
